SYNCOMF share price, P/E, ROE & financials

Syncom Formulations (India) (SYNCOMF) had a P/E of 21.5× on 6 Nov 2026, below the industry P/E of 28.7×, and the shares are 27% below their 52-week high. Sales and net profit grew 29% and 56% a year over 3 years; its ROCE of 24% is the highest among the 7 largest Drug Manufacturers (Specialty & Generic) peers. It carries very little debt, and its dividend yield is 0.5%. It is a small-cap company with a market cap of ₹1,899 Cr, ranked 61st of 154 Drug Manufacturers (Specialty & Generic) companies by market cap; the shares rose 27% over the past year.

As of 6 Nov 2026Prices are delayed about 15 minutes; fundamentals are from the quarter ended Jun 2026.How we calculate this

past year

Open: ₹20.78
Day high: ₹21.18
Day low: ₹19.80
Prev. close: ₹20.88
Volume: 72.5 L

Health check

5 good · 1 fair

ReturnsIn line
+27.5% over a year, better than 4 of 7 peers.
Price tagCheaper
P/E 21.5 vs industry 28.7.
GrowthStrong
Sales +29.4%, profit +56.1% a year over 3 years.
ProfitabilityStrong
ROCE 23.7% vs peer median 17.9%.
Balance sheetSolid
Practically debt-free, Piotroski 6 of 9.
Red flagsNone found
No warning signs in the headline numbers.

Compared with 7 industry peers. Computed from reported figures. Educational, not a recommendation.

Drug Manufacturers - Specialty & Generic

153 listed peers. Screen the industry

Small cap

₹1,899 Cr, #61 of 154 in its industry by size.

Moves with the market

Beta 0.93 vs the NIFTY 50: tracks the market closely.

Key metrics

Last 12 months to Jun 2026: sales ₹498 Cr · profit ₹86 Cr

Market cap: ₹1,899 Cr; Small cap
P/E: 21.5; Industry 28.7
Price to book: 4.54; Peers 4.99
Dividend yield: 0.50%
ROE: 20.2%; Peers 14.7%
ROCE: 23.7%; Peers 17.9%
Debt to equity: 0.00; Debt ₹1.47 Cr
EPS (TTM): ₹0.94; Face value ₹1
OPM (TTM): 17.6%; Net margin 17.2%
Sales growth: +7.4%; Latest quarter vs a year ago
Profit growth: +57.7%; Latest quarter vs a year ago
Price to sales: 3.81; EV/EBITDA 21.1

Strengths

Return on equity of 20.2%.
Return on capital employed of 23.7%.
Practically debt-free.
Quarterly profit up 57.7% on a year ago.
P/E of 21.5 against an industry P/E of 28.7.

No obvious red flags in the headline numbers.

Derived automatically from reported figures. Not a recommendation.

About Syncom Formulations (India)

Syncom Formulations (India) Limited manufactures, markets, and sells pharmaceutical formulation products in India and internationally. It operates through Manufacturing and Dealing in Pharmaceutical Drug and Formulations, Trading of Commodities, and Renting of Properties segments. The company offers antibiotics/antiinfectives, anthelmintics, antimalarial, cardiac, derma, gastro, dry syrups and suspensions, creams, gel, ORS, jelly, gynae, inhalers, opthal,…

Headquarters: Indore
Employees: 902
Sector: Healthcare
ISIN: INE312C01025
Website: syncomformulations.com

Price range

52 weeks

₹10.21₹27.49

Today

₹19.80₹21.18

Avg volume (3M): 1.9 Cr
1-year return: plus 27.5%
From 52-week high: minus 26.5%

Peers · Drug Manufacturers - Specialty & Generic

Compare with peers Screen the whole industry

Company
SUNPHARMASun Pharmaceutical Industries	1,860.00	plus 1.69%	4,46,276	40.7	4.99	17.9%	13.1%	28.2%	10.4%	10.6%	0.86%	plus 8.2%
DIVISLABDivi's Laboratories	10,320.50	plus 1.78%	2,73,977	93.6	16.35	19.0%	16.2%	34.9%	11.0%	12.1%	0.29%	plus 49.0%
TORNTPHARMTorrent Pharmaceuticals	4,750.00	plus 0.85%	1,80,675	80.2	9.83	9.1%	15.7%	33.7%	13.3%	20.2%	0.80%	plus 31.7%
LAURUSLABSLaurus Labs	2,340.00	minus 0.26%	1,26,433	94.4	20.86	19.5%	24.0%	30.4%	3.8%	4.0%	0.09%	plus 138.6%
ZYDUSLIFEZydus Lifesciences	1,197.90	plus 0.41%	1,19,491	28.6	4.29	19.0%	14.7%	26.2%	16.5%	37.0%	0.08%	plus 22.8%
DRREDDYDr. Reddy's Laboratories	1,373.00	plus 0.51%	1,14,462	40.9	2.96	14.2%	7.3%	15.9%	11.0%	−1.7%	0.58%	plus 13.8%
CIPLACipla	1,411.00	plus 0.49%	1,13,993	39.4	3.22	14.9%	8.3%	17.3%	7.2%	11.5%	0.92%	minus 6.6%
SYNCOMFSyncom Formulations (India)	20.20	minus 3.26%	1,899	21.5	4.54	23.7%	20.2%	19.7%	29.4%	56.1%	0.50%	plus 27.5%
Median of 7 peers	–	0.51%	1,26,433	40.9	4.99	17.9%	14.7%	28.2%	11.0%	11.5%	0.58%	22.8%

Quarterly results

Consolidated, ₹ crore

SalesSelect a row below to chart it

Jun 25	Sep 25	Dec 25	Mar 26	Jun 26
117	122	115	135	126
101	103	93.9	113	99.3
15.8	18.4	21.2	22	26.2
13.5%	15.1%	18.4%	16.3%	20.9%
6	5.3	5.5	14.6	7.8
0.3	0.3	0.3	0.4	0.2
1.3	1.4	1.4	2.5	1.5
0	–	–	−0	–
20.3	22	25.1	33.7	32.3
22.4%	24.7%	24.6%	25.3%	23.0%
15.8	16.6	18.9	25.2	24.8
0.17	0.18	0.23	0.27	0.26

Profit & loss

Yearly, ₹ crore

Sales CAGR 3Y: +29.4%
Profit CAGR 3Y: +56.1%
EPS CAGR 3Y: +55.3%
ROE: 20.2%

Net profitSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
222	259	457	482
–	+16.5%	+76.4%	+5.3%
201	229	398	397
21	29.9	59.3	84.2
9.4%	11.5%	13.0%	17.5%
13.1	12.4	11.7	17.5
3.2	4.4	0.7	0.6
4.5	4.7	5.2	6.5
0.2	0.7	0.4	6.6
26.6	34	65.5	101
24.5%	25.4%	24.5%	24.4%
20.1	25.3	49.4	76.4
–	+26.1%	+95.3%	+54.6%
0.22	0.27	0.53	0.81

Forecast

Your assumptions, not a prediction

Balance sheet

At each financial year end, ₹ crore

Total assetsSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
94	94	94	94
162	194	248	321
83.2	72.5	4.6	1.5
38.6	44	66.5	117
378	405	413	534
70.6	72.5	78.1	90.8
27.3	0.2	0.5	1
73.2	3.5	16.2	17.3
70.8	131	89.9	113
136	197	229	312
378	405	413	534

Cash flow

Yearly, ₹ crore

Cash from operationsSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
10.5	−6	23.4	58.1
−45	83	−18.2	−50.6
35	−14.6	−67.9	−3
0.6	62.5	−62.7	4.4
−20.6	−8.1	−10	−11.7
−10.1	−14.1	13.5	46.4
−2.8	–	–	–

Shareholding pattern

Source: NSE filings

50.6%

promoters

Promoters50.57%
Public49.43%
As of 30 Sep 2026

Quarter	Promoters	Public	Promoter change
30 Sep 2026	50.57%	49.43%	0.00
30 Jun 2026	50.57%	49.43%	0.00
31 Mar 2026	50.57%	49.43%	0.00
31 Dec 2025	50.57%	49.43%	0.00
30 Sep 2025	50.57%	49.43%	–

Major shareholders

NSE filing

Filings & events

News

No recent news coverage found.

My notes

Private to you